Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02390414
Other study ID # 11-056
Secondary ID
Status Completed
Phase
First received
Last updated
Start date May 2011
Est. completion date September 2020

Study information

Verified date March 2023
Source Dana-Farber Cancer Institute
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The purpose of this observational study is to compare overall survival in older adults with myelodysplastic syndromes (MDS) who receive reduced intensity conditioning hematopoietic stem cell transplant (RIC HSCT) versus those who do not receive HSCT.


Description:

MDS is a hematologic malignancy characterized by cytopenias, bone marrow failure, and a risk of transformation to acute myeloid leukemia (AML). HSCT is the only curative therapy for MDS. Despite its increasing use among older patients (age greater than 60), more data are needed to assess outcomes of HSCT in older adults compared to other therapies. In this observational study, patients with MDS presenting at the study institutions are screened for disease characteristics that indicate that they are potentially appropriate for HSCT (both high-risk disease and fit for the procedure). Patients who meet inclusion and exclusion criteria and agree to participate in the study are entered into a clinical database and followed for overall survival. Patients also complete quality of life (QoL) assessments at enrollment and two years afterward, with the goal of investigating potential relationships between QoL and MDS treatment (HSCT vs. non-HSCT strategies).


Recruitment information / eligibility

Status Completed
Enrollment 290
Est. completion date September 2020
Est. primary completion date September 2020
Accepts healthy volunteers No
Gender All
Age group 60 Years to 75 Years
Eligibility Inclusion Criteria: - Histologically-confirmed diagnosis of: - Primary or secondary MDS using the World Health Organization (WHO) 2008 classification: - Refractory cytopenia with unilineage dysplasia - Refractory Anemia (RA) - Refractory Neutropenia (RN) - Refractory Thrombocytopenia (RT) - Refractory Anemia with Ring Sideroblasts (RARS) - Refractory Cytopenia with Multilineage Dysplasia (RCMD) - Refractory Anemia with Excess Blasts-1 (RAEB-1) - Refractory Anemia with Excess Blasts-2 (RAEB-2) - MDS with isolated del (5q) - MDS-Unclassified (MDS-U) - Another of the following related disorders: - Chronic Myelomonocytic leukemia (CMML) - Myelodysplastic/myeloproliferative neoplasm, unclassifiable (MDS/MPD-U) - Age 60 to 75 years - Any of the following (high-risk characteristics): - Intermediate-2 or High-Risk on International Prognostic Scoring System (IPSS) - Secondary MDS (any karyotype) - Documented non-IPSS intermediate- or poor-prognosis karyotype including: - +8 - t(11q23) - Rea 3q - +19 - 3 or greater abnormalities - del(7q) - -5 - t(5q) - Documented significant cytopenia for at least four months prior to enrollment, defined by the following criteria: - Red Blood Cell (RBC) Transfusion Dependence: four or more units of RBC transfusions within an eight-week period for symptomatic anemia with hemoglobin of = 9.0 g/dL; OR - Severe Anemia: average of two or more hemoglobin values = 8 g/dL within an eight-week period not influenced by RBC transfusions (i.e., must be seven days post transfusion); OR - Severe Thrombocytopenia: average of two or more platelet counts = 50 × 109/L within an eight-week period not influenced by platelet transfusions (i.e., must be at least three days post- transfusion) or a clinically significant hemorrhage requiring platelet transfusions within the prior four months; OR - Severe Neutropenia: average of two or more absolute neutrophil counts (ANC) = 500 within an eight-week period, or a clinically significant infection requiring IV antibiotics in the setting of ANC = 1000 within the prior four months. - Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2. - Adequate organ function to permit RIC HSCT as indicated by the following: - Serum bilirubin = 2.5 mg/dL (except when Gilbert's syndrome or MDS-related hemolysis suspected). - Aspartate aminotransferase (AST) and Alanine Aminotransferase (ALT) = 2.5 times the upper limit of normal (ULN). - Serum creatinine = 2.0 mg/dL. - Seemingly sufficient baseline cardiac function to undergo HSCT (no echocardiogram required). - Seemingly sufficient baseline pulmonary function to undergo HSCT (no pulmonary function tests required). - Seemingly sufficient neuro-psychiatric function to undergo HSCT (no specific neuro-psychiatric evaluation required). - Willingness to undergo human leukocyte antigen (HLA)-typing and consider subsequent HSCT. - Willingness and ability to give informed consent. Exclusion Criteria: - Known baseline conversion to AML (eg, = 20% peripheral or marrow blasts). - Knowledge of potential donor status at study entry. Of note, knowledge of HLA status WITHOUT a related or unrelated search is allowed. - History of prior malignancy within the past year, except for adequately-treated carcinoma in situ of uterine cervix, basal cell or squamous cell skin cancer. - Any severe concurrent disease, infection, or comorbidity that, in the judgment of the principal investigator, would make the patient inappropriate for HSCT at the time of study entry. - Psychiatric disorders including dementia that would preclude obtaining informed consent or the ability to participate in an ongoing research study.

Study Design


Locations

Country Name City State
United States Beth Israel Deaconess Medical Center Boston Massachusetts
United States Dana Farber Cancer Institute Boston Massachusetts
United States Massachusetts General Hospital Boston Massachusetts

Sponsors (1)

Lead Sponsor Collaborator
Dana-Farber Cancer Institute

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Overall Survival To prospectively compare the overall survival of patients in the HSCT group to that of patients in the non-HSCT group. 3 Years
See also
  Status Clinical Trial Phase
Completed NCT02550535 - A Phase I/II Study of Gene-modified WT1 TCR Therapy in MDS & AML Patients Phase 1/Phase 2
Completed NCT00186342 - Sibling and Unrelated Donor Hematopoietic Cell Transplant in Hematologic Malignancies N/A
Completed NCT00528983 - Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myelogenous Leukemia Phase 1
Completed NCT01355913 - Screening and Genetic Monitoring of Patients With Myelodysplastic Syndromes (MDS) Under Different Treatment Modalities by Cytogenetic Analyses of Circulating CD34+Cells
Withdrawn NCT04985656 - A Study of Pevonedistat Combined With Decitabine and Cedazuridine in Adults With Higher-risk Myelodysplastic Syndromes Phase 2
Completed NCT01736683 - Study of Sotatercept for the Treatment of Anemia in low-or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) or Non-proliferative Chronic Myelomonocytic Leukemia (CMML) Phase 2
Completed NCT02333058 - Treosulfan-based Conditioning in Paediatric Patients With Haematological Malignancies Phase 2
Completed NCT01135849 - B-Receptor Signaling in Cardiomyopathy N/A
Withdrawn NCT04395092 - Haplo-identical Natural Killer (NK) Cells to Prevent Post-Transplant Relapse in AML and MDS (NK-REALM) Phase 2
Completed NCT01885897 - IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT Phase 1/Phase 2
Recruiting NCT05092451 - Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances Phase 1/Phase 2
Recruiting NCT05884333 - Cord Blood Transplant in Adults With Blood Cancers Phase 2
Completed NCT01326377 - ON 01910.Na for Intermediate1-2, or High Risk Trisomy 8 Myelodysplastic Syndrome (MDS) Phase 2
Completed NCT02966782 - A Study Evaluating Venetoclax Alone and in Combination With Azacitidine in Participants With Relapsed/Refractory Myelodysplastic Syndromes (MDS) Phase 1
Recruiting NCT02779569 - A Clinical Trial Evaluating the Efficacy of Ultra Low Dose of Decitabine in Myelodysplastic Syndromes (MDS) N/A
Recruiting NCT02099669 - Red Blood Cell Transfusion Thresholds and QOL in MDS N/A
Completed NCT01392989 - Post T-plant Infusion of Allogeneic Cytokine Induced Killer (CIK) Cells as Consolidative Therapy in Myelodysplastic Syndromes/Myeloproliferative Disorders Phase 2
Not yet recruiting NCT06398457 - Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies Early Phase 1
Recruiting NCT02775383 - The National Myelodysplastic Syndromes (MDS) Study
Recruiting NCT04275518 - A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS. Phase 1